Navigation Links
Naltrexone in Medical News

Anti-Craving Drug, Naltrexone Helps Women Quit Smoking

A new study finds that the anti-craving drug, Naltrexone may lessen cessation-related weight gain and negative moods and women who are trying to quit smoking appear //to benefit more than men. As a first step towards individualized medicine, scientists are focusing on gender differences in nicotine...

-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments-

... References to Contrave16 and Contrave48 relate to combinations containing naltrexone SR 16mg or naltrexone SR 48mg, respectively. Trial Design and Results of COR Phase 3 Tr...

Addiction Drug May Help Ease Fibromyalgia

... In small study, naltrexone offered some women relief FRIDAY, Apri...y News) -- Low doses of an inexpensive drug called naltrexone -- already used for years to treat drug addiction ...e drugs." Younger said he got the idea to study naltrexone after hearing that some other doctors had success ...

Suppressing the compulsion to steal

...d randomized them to receive treatment with either naltrexone or placebo. naltrexone is a drug that blocks the effects of endogenous op.... They found that after eight weeks of treatment, naltrexone was able to reduce the urges to steal and stealing...

Drug commonly used for alcoholism, drug addiction, curbs urges of compulsive stealers

...d an eight-week, double-blind study of 25 men and women ages 17-75, who spent an average of at least one hour a week stealing. Those who took the drug naltrexone (mean dose of 117mg/day) reported significantly greater decline in stealing behavior compared to those taking placebo. The research is published in ...

Hormone Drug May Help Drinkers Stay Sober

...humans for the treatment of hyperprolactinemia." Only three medications have FDA approval for treating alcohol dependence -- disulfiram (Antabuse), naltrexone (Depade, ReVia), and acamprosate (Campral). The U.S. National Institutes of Health estimates that almost 18 million people in the United States --...

UCSF Gallo Study Finds Hormone Disorder Drug Could Help Drinkers Stay Sober

...t, according to the National Institutes of Health. But there are just three medications approved to treat alcohol dependence -- disulfiram (Antabuse), naltrexone (Depade, ReVia), and acamprosate (Campral). Lead author of the study is Sebastien Carnicella, PhD, postdoctoral fellow at the Gallo Center. Co-aut...

King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion

...morphine sulfate extended-release with sequestered naltrexone hydrochloride), both of which are designed to resi...morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules ALO-01(morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules (EMBEDA(TM)), Alpharma's p...

Prescribed Meds Still Best Treatment for Alcoholism

...heir relapse rates appeared to be more a function of inadequate exposure to naltrexone and less influenced by CBI," he added. Overall, specialized CBI did not ...ion adherence rates," Zweben said. The findings show that combing MM and naltrexone could benefit a large percentage of alcohol-dependent patients. "Alcohol...

Scientific poster abstracts from the 24th annual meeting of the American Academy of Pain Medicine

... 2005 Treatment Episode Data Set (TEDS) 157 Evaluation of Lacosamide in Diabetic Neuropathic Pain Trials 158 A Pilot Study to Select a Dose of naltrexone Hydrochloride That Will Reduce Subjective Euphoric Effects of Oxycodone Hydrochloride in Non-Dependent, Opioid-Preferring Subjects 159 Tapentadol ...
Naltrexone in Medical Technology

Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)

- Improved Pharmacokinetic Characteristics of Naltrexone SR Associated with Better Tolerability in Clinical Trials - PHOENIX, Oct. 6 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX ), a biopharmaceutical company focused on the treatment of obesity and other ce...

Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting

BRIDGEWATER, N.J., Sept. 9 /PRNewswire-FirstCall/ -- Alpharma Inc. (NYSE: ALO ), a global specialty pharmaceutical company, today announced results from its Phase III pivotal efficacy trial that showed ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochl...

Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session

TAMPA, Fla., May 8 /PRNewswire-FirstCall/ -- Alpharma Inc. (NYSE: ALO ), a global specialty pharmaceutical company, today announced results from clinical trials that showed ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) capsules demonstrated ...

King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use

...rally well tolerated. Evaluation of Plasma naltrexone Concentrations Resulting From Use of ALO-01 (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules for Chronic Pain EMBE...n of morphine sulfate surrounding an inner core of naltrexone hydrochloride. EMBEDA(TM) is intended to treat mo...

Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team

...proof-of-concept Phase 2 trials for OREX-003 (zonisamide and olanzapine to mitigate antipsychotic-associated weight gain) and OREX-004 (fluoxetine and naltrexone to reduce symptoms of obsessive- compulsive disorder) will be discontinued effective immediately. The Company intends to maintain its intellectual pr...

Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule

...besity product candidate, Contrave(R), is a combination of bupropion SR and naltrexone in a proprietary SR formulation that also appears to result in improved tolerability compared to the legacy naltrexone IR formulation. Contrave currently is being studied in four Phase III clini...

Alpharma Presents Positive Pharmacokinetic Study Results of Its Investigational Abuse-Deterrent, Extended-Release Opioid

...stent with a sustained-release formulation and were similar to previous study results for KADIAN(R) (morphine sulfate extended-release) Capsules. Most naltrexone levels were below the assay measurement limits. Adverse events, reported in five subjects, were mild to moderate in intensity and resolved without tre...

Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23

...an Diabetes Association (ADA) in Chicago, IL. Contrave data can be found in category 20B, poster number 45LB entitled, "Weight Loss with Bupropion and naltrexone Improves Markers of Insulin-Resistance." Contrave is a proprietary fixed dose combination of bupropion SR (sustained release) and Orexigen's novel f...
Naltrexone in Biological Technology

Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions

...uated the additional weight loss of Contrave (32mg naltrexone SR/360mg bupropion SR) when added to an intensive ...profile consistent with its individual components, naltrexone and bupropion, two drugs that have been used separ...hich utilized the immediate release formulation of naltrexone as opposed to the proprietary SR formulation used ...

Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association and Endocrine Society Annual Scientific Meetings

...yer, M.D., M.P.H., The New York Obesity Research Center, St. Luke's Roosevelt Hospital Center, New York, N.Y. Title: "Combination Therapy with naltrexone + Bupropion Causes Significant Weight Loss and Improves Cardiometabolic Parameters in Obese Individuals: A Randomized Phase 3 Study Over 56 We...

Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results

...t (p<0.001). Contrave was generally well tolerated by patients, with an overall safety profile that was consistent with its individual components, naltrexone and bupropion. The most frequently observed treatment-emergent adverse events for patients on study drug were nausea, headache, constipation and dizz...

Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints

...ea was 4.6%, an improvement over the 11.1% discontinuation rate seen in the Phase 2 trial (NB-201) which utilized the immediate release formulation of naltrexone as opposed to the proprietary SR formulation used in this trial. The most frequently observed treatment-emergent adverse events for patients on study...

Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)

...n patent (U.S. Patent No. 7,375,111) which was issued by the USPTO in May 2008 and broadly covers sustained release (SR) compositions of bupropion and naltrexone combined in a single dosage form. The Weber/Cowley methods patent will provide protection for Contrave through mid 2024. "The issuance of this ...

Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results

...008, which covers SR compositions of bupropion and naltrexone combined in a single dosage form through March 202...ivity. OREX-004 is a proprietary SR formulation of naltrexone plus fluoxetine. The Phase 2a clinical trial, NF- ...xone successfully achieved key objectives (lowered naltrexone Cmax, increased Tmax, comparable AUC). Additionall...

Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting

... 11:00-11:15 a.m. MT Poster Presentation Abstract: 585-P Title: "Relative Bioavailability of Sustained-release (SR) versus Immediate-release (IR) naltrexone (NAL) Formulations in Healthy Obese Volunteers: Implications for Improved Tolerability?" Time: 5:30-7:30 p.m. MT Monday, October 6 Oral Presentat...

New MedPredict Report Suggests Market for Alcoholism Therapies is Underestimated

...rding to this physician panel, there are a number of factors stymieing biopharmaceutical companies, including the lackluster commercial performance of naltrexone and acamprosate, a lack of clear FDA guidance on trial design and resulting indications, the stigma associated with alcoholism and associated corporat...

DNA Predicts Reaction to Drug That Fights Alcohol Dependence

...ing gratification from alcohol. Not only did patients who were treated with naltrexone and have the Asp40 gene variant go without harmful drinking for a longer pe...al without the therapy. Gene variant carriers of all ethnicities who took naltrexone were more likely than their counterparts to have a good clinical result. Ho...
Other Tags
(Date:5/28/2015)... May 28, 2015 The CEO and ... a just launched blog series which provides analysis on ... on the “R. Bruce Dalglish” profile on Blogger.com, this ... Bruce Dalglish’s corporate experience. , “Throughout my business ... cultures have upon the overall success of businesses,” stated ...
(Date:5/28/2015)... May 28, 2015 More than 300 ... will raise money to help the Muscular Dystrophy Association ... dystrophy and related life-threatening diseases that limit muscle strength ... mobile program. , From June 1 to June 30, ... customers the opportunity to help send local children affected ...
(Date:5/28/2015)... 28, 2015 ZH Healthcare (ZH), a ... it is releasing BlueEHS, the Electronic Health Solution, on ... for the benefit of all AWS users worldwide. ... first of its kind, Freemium, SaaS, Electronic Health Solution ... (EHR) with an integrated practice management system (PMS), e-Rx, ...
(Date:5/28/2015)... CompanionDx , a Houston-based ... it will present their integrated solution of next-generation ... annual American Society of Clinical Oncology (ASCO) in ... DNA in a patient’s tumor via a small ... changes or somatic mutations. Pharmacogenomics testing establishes a ...
(Date:5/28/2015)... Sexual Health Innovations, a nonprofit ... health and wellbeing in the United States, announced ... (USF) will be the first institution to adopt ... reporting system. , Callisto is designed to ... experience for college sexual assault survivors, to give ...
Breaking Medicine News(10 mins):Health News:R. Bruce Dalglish, CEO of Alliance Hospice, Introduces New Blog Series On Positive Corporate Culture 2Health News:sweetFrog and MDA Join Forces to Send Kids with Muscle Disease to Summer Camp 2Health News:sweetFrog and MDA Join Forces to Send Kids with Muscle Disease to Summer Camp 3Health News:BlueEHS, the Electronic Health Solution, now available on Amazon AWS Market place 2Health News:BlueEHS, the Electronic Health Solution, now available on Amazon AWS Market place 3Health News:CompanionDx® Launches Integrated Genomic Solution at ASCO Meeting 2Health News:University of San Francisco Becomes First in the Nation to Adopt College Sexual Assault Reporting System 2Health News:University of San Francisco Becomes First in the Nation to Adopt College Sexual Assault Reporting System 3
(Date:5/10/2015)... -- Fingerprint Cards (FPC) has received an order ... distributor World Peace Industrial Group (WPI), part of WPG Holdings. ... . Deliveries are planned to take place during Q3 ... in China . The order value of ... + 1 000 MSEK for 2015.   Jörgen Lantto, ...
(Date:5/7/2015)... 2015 Fingerprint Cards (FPC) ... FPC1035, FPC,s smallest touch fingerprint sensors to date.  ... for integration on the backside of the phone, ... possibilities to integrate touch fingerprint sensors in the ... possibilities for module manufacturers to customize the look ...
(Date:5/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, reminds investors and media that  Mr. ...  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of nine ... Global Fraud: Where is the Trust in Cyberspace? ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
Other Contents